Literature DB >> 16730454

Surface NK receptors and their ligands on tumor cells.

Lorenzo Moretta1, Cristina Bottino, Daniela Pende, Roberta Castriconi, Maria Cristina Mingari, Alessandro Moretta.   

Abstract

The identification of MHC-class I-specific inhibitory receptors in humans and mice provided a first explanation of why NK cells can kill target cells that have lost or underexpress MHC-class I molecules but spare normal cells. However, the molecular basis of NK-mediated recognition and tumor cell killing revealed a higher degree of complexity. Thus, under pathological conditions, NK cells may express insufficient amounts of triggering receptors and target cells may or may not express ligands for such receptors. Here we briefly illustrate the main NK receptors and their cellular ligands and we delineate the major receptor/ligands interactions leading to NK cell activation and tumor cell lysis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16730454     DOI: 10.1016/j.smim.2006.03.002

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  96 in total

Review 1.  Mesenchymal stem cells: Mechanisms of immunomodulation and homing.

Authors:  Hiroshi Yagi; Alejandro Soto-Gutierrez; Biju Parekkadan; Yuko Kitagawa; Ronald G Tompkins; Naoya Kobayashi; Martin L Yarmush
Journal:  Cell Transplant       Date:  2010-06-03       Impact factor: 4.064

2.  Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation.

Authors:  Andrea De Maria; Federica Bozzano; Claudia Cantoni; Lorenzo Moretta
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

Review 3.  Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors.

Authors:  H J Symons; E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2008-08-04       Impact factor: 5.483

4.  Homo-oligomerization of the activating natural killer cell receptor NKp30 ectodomain increases its binding affinity for cellular ligands.

Authors:  Julia Herrmann; Hannah Berberich; Jessica Hartmann; Steffen Beyer; Karen Davies; Joachim Koch
Journal:  J Biol Chem       Date:  2013-11-25       Impact factor: 5.157

5.  Drug-induced hyperploidy stimulates an antitumor NK cell response mediated by NKG2D and DNAM-1 receptors.

Authors:  Andrea Acebes-Huerta; Seila Lorenzo-Herrero; Alicia R Folgueras; Leticia Huergo-Zapico; Carlos Lopez-Larrea; Alejandro López-Soto; Segundo Gonzalez
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

6.  The Stalk Domain of NKp30 Contributes to Ligand Binding and Signaling of a Preassembled NKp30-CD3ζ Complex.

Authors:  Stefanie Memmer; Sandra Weil; Steffen Beyer; Tobias Zöller; Eike Peters; Jessica Hartmann; Alexander Steinle; Joachim Koch
Journal:  J Biol Chem       Date:  2016-10-17       Impact factor: 5.157

Review 7.  Natural killer cell receptors and their ligands in liver diseases.

Authors:  Satoshi Yamagiwa; Hiroteru Kamimura; Takafumi Ichida
Journal:  Med Mol Morphol       Date:  2009-03-18       Impact factor: 2.309

8.  Structure of natural killer receptor 2B4 bound to CD48 reveals basis for heterophilic recognition in signaling lymphocyte activation molecule family.

Authors:  C Alejandro Velikovsky; Lu Deng; Lukasz K Chlewicki; Marisa M Fernández; Vinay Kumar; Roy A Mariuzza
Journal:  Immunity       Date:  2007-10-18       Impact factor: 31.745

9.  Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions.

Authors:  Trinidad Garcia-Iglesias; Alicia Del Toro-Arreola; Benibelks Albarran-Somoza; Susana Del Toro-Arreola; Pedro E Sanchez-Hernandez; Maria Guadalupe Ramirez-Dueñas; Luz Ma Adriana Balderas-Peña; Alejandro Bravo-Cuellar; Pablo C Ortiz-Lazareno; Adrian Daneri-Navarro
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

10.  Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells.

Authors:  Gal Markel; Rachel Seidman; Michal J Besser; Naama Zabari; Rona Ortenberg; Ronnie Shapira; Avraham J Treves; Ron Loewenthal; Arie Orenstein; Arnon Nagler; Jacob Schachter
Journal:  PLoS One       Date:  2009-05-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.